WO2004056306A3 - Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques - Google Patents

Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques Download PDF

Info

Publication number
WO2004056306A3
WO2004056306A3 PCT/DE2003/004204 DE0304204W WO2004056306A3 WO 2004056306 A3 WO2004056306 A3 WO 2004056306A3 DE 0304204 W DE0304204 W DE 0304204W WO 2004056306 A3 WO2004056306 A3 WO 2004056306A3
Authority
WO
WIPO (PCT)
Prior art keywords
prophylaxis
dopa
derivatives
diseases
pharmacologically
Prior art date
Application number
PCT/DE2003/004204
Other languages
German (de)
English (en)
Other versions
WO2004056306A2 (fr
Inventor
Rudolf-Giesbert Alken
Original Assignee
Turicum Drug Dev Ag
Rudolf-Giesbert Alken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turicum Drug Dev Ag, Rudolf-Giesbert Alken filed Critical Turicum Drug Dev Ag
Priority to EP03785594A priority Critical patent/EP1615631A2/fr
Priority to JP2004561055A priority patent/JP2006511558A/ja
Priority to AU2003294664A priority patent/AU2003294664A1/en
Priority to CA002513077A priority patent/CA2513077A1/fr
Priority to US10/539,793 priority patent/US20070082953A1/en
Priority to EA200500957A priority patent/EA200500957A1/ru
Priority to MXPA05006409A priority patent/MXPA05006409A/es
Publication of WO2004056306A2 publication Critical patent/WO2004056306A2/fr
Publication of WO2004056306A3 publication Critical patent/WO2004056306A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilisation de L-DOPA, de ses dérivés ou de ses sels physiologiquement acceptables pour la prophylaxie de maladies psychotiques et pour le traitement de maladies provoquées par une perturbation du transport de la tyrosine ou par une perturbation de la tyrosine décarboxylase. La présente invention concerne en outre des compositions pharmaceutiques qui contiennent L-DOPA, ses dérivés ou ses sels physiologiquement acceptables pour la prophylaxie de maladies psychotiques, ainsi que des additifs et adjuvants pharmaceutiquement acceptables. Elle concerne encore la combinaison de L-DOPA, de ses dérivés ou de ses sels physiologiquement acceptables avec des inhibiteurs d'enzymes pour la prophylaxie de maladies psychotiques et pour le traitement de maladies provoquées par une perturbation du transport de la tyrosine ou par une perturbation de la tyrosine décarboxylase, ainsi que des compositions pharmaceutiques correspondantes pour la prophylaxie de maladies psychotiques et pour le traitement de maladies qui sont provoquées par une perturbation du transport de la tyrosine ou par une perturbation de la tyrosine décarboxylase.
PCT/DE2003/004204 2002-12-19 2003-12-18 Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques WO2004056306A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03785594A EP1615631A2 (fr) 2002-12-19 2003-12-18 Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques
JP2004561055A JP2006511558A (ja) 2002-12-19 2003-12-18 精神病疾患を予防するためのｌ−ドーパ、その誘導体およびこれらの化合物を含有する医薬品の使用
AU2003294664A AU2003294664A1 (en) 2002-12-19 2003-12-18 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
CA002513077A CA2513077A1 (fr) 2002-12-19 2003-12-18 Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques
US10/539,793 US20070082953A1 (en) 2003-12-18 2003-12-18 Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
EA200500957A EA200500957A1 (ru) 2002-12-19 2003-12-18 Применение l-допа, его производных и лекарственных средств, содержащих эти соединения, для профилактики психотических заболеваний
MXPA05006409A MXPA05006409A (es) 2002-12-19 2003-12-18 Uso de l-dopa, de sus derivados y medicamentos comprendiendo estos compuestos para la prevencion de enfermedades psicoticas.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10261808A DE10261808A1 (de) 2002-12-19 2002-12-19 Verwendung von L-DOPA, seiner Derivate und diese Verbindungen enthaltender Arzneimittel zur Prophylaxe psychotischer Erkrankungen
DE10261808.9 2002-12-19

Publications (2)

Publication Number Publication Date
WO2004056306A2 WO2004056306A2 (fr) 2004-07-08
WO2004056306A3 true WO2004056306A3 (fr) 2004-11-11

Family

ID=32478131

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/004204 WO2004056306A2 (fr) 2002-12-19 2003-12-18 Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques

Country Status (10)

Country Link
EP (1) EP1615631A2 (fr)
JP (1) JP2006511558A (fr)
CN (1) CN1756542A (fr)
AU (1) AU2003294664A1 (fr)
CA (1) CA2513077A1 (fr)
DE (1) DE10261808A1 (fr)
EA (1) EA200500957A1 (fr)
MX (1) MXPA05006409A (fr)
PL (1) PL377524A1 (fr)
WO (1) WO2004056306A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
ME02508B (fr) 2006-02-17 2017-06-20 Ratiopharm Gmbh Derives de catecholamine deuteres et medicaments comprenant de tels composes
CN105078952A (zh) * 2015-08-10 2015-11-25 中国康复研究中心 一种左旋多巴制剂及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2001060A (en) * 1977-07-01 1979-01-24 Merrell Toraude & Co alpha -Acetylenic Amino Acids
US5330895A (en) * 1989-10-12 1994-07-19 Ramirez Victor D Detection reagent and antibody specific for dopamine releasing protein

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52102431A (en) * 1976-02-25 1977-08-27 Kyowa Hakko Kogyo Co Ltd Remedies for mental disorder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2001060A (en) * 1977-07-01 1979-01-24 Merrell Toraude & Co alpha -Acetylenic Amino Acids
US5330895A (en) * 1989-10-12 1994-07-19 Ramirez Victor D Detection reagent and antibody specific for dopamine releasing protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 198401, Derwent World Patents Index; Class B05, AN 1984-001816, XP002278318 *
GERLACH J ET AL: "The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.", PSYCHOPHARMACOLOGIA. GERMANY, WEST 14 OCT 1975, vol. 44, no. 1, 14 October 1975 (1975-10-14), pages 105 - 110, XP008030065, ISSN: 0033-3158 *
HALE M S ET AL: "LOW DOSE PERPHENAZINE AND LEVODOPA/CARBIDOPA THERAPY IN A PATIENT WITH PARKINSONISM AND A PSYCHOTIC ILLNESS", JOURNAL OF NERVOUS AND MENTAL DISEASE, WILLIAMS AND WILKINS, US, vol. 168, no. 5, 1980, pages 312 - 314, XP008020514, ISSN: 0022-3018 *
SANDOR, PAUL ET AL: "Remoxipride in the treatment of levodopa-induced psychosis", JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (1996), 16(5), 395-399, XP008030094 *

Also Published As

Publication number Publication date
EA200500957A1 (ru) 2006-02-24
EP1615631A2 (fr) 2006-01-18
WO2004056306A2 (fr) 2004-07-08
PL377524A1 (pl) 2006-02-06
CN1756542A (zh) 2006-04-05
JP2006511558A (ja) 2006-04-06
MXPA05006409A (es) 2006-05-31
AU2003294664A1 (en) 2004-07-14
CA2513077A1 (fr) 2004-07-08
DE10261808A1 (de) 2004-07-08

Similar Documents

Publication Publication Date Title
TW200613306A (en) Imidazotriazines as protein kinase inhibitors
WO2004005281A8 (fr) Inhibiteurs de tyrosine kinases
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
UA97795C2 (uk) Дейтеровані похідні катехоламіну і медикаменти, що містять згадані сполуки
NO20053470L (no) Triazolopyridaziner som proteinkinase-inhibitorer
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
WO2004033455A3 (fr) Sels succiniques d&#39;inhibiteurs heterocycliques de dpp-iv
WO2006066913A3 (fr) Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
EA200900613A1 (ru) Спирокетоновые ингибиторы ацетил-коа-карбоксилаз
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
WO2011058474A8 (fr) Inhibiteurs de n1-pyrazolospirocétone acétyl-coa carboxylase
NO20075113L (no) Proteinkinaseinhibitorer
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
EA200600833A1 (ru) Тиазолидиноны, их получение и применение как фармацевтических агентов
WO2003051838A3 (fr) Inhibiteurs de la proteine kinase
NO20076037L (no) Nye tiazolidinoner uten basisk nitrogen, deres fremstilling og anvendelse som farmasoytiske midler
DE602007010038D1 (de) Pyrimidylderivate als proteinkinaseinhibitoren
WO2003072537A3 (fr) Inhitibteurs selectifs de la proteine tyrosine phosphatatase
WO2004056306A3 (fr) Utilisation de l-dopa, de ses derives et de medicaments contenant lesdits composes pour la prophylaxie de maladies psychotiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 377524

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006409

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 169204

Country of ref document: IL

Ref document number: 2004561055

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038A66148

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003785594

Country of ref document: EP

Ref document number: 541048

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003294664

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2513077

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200500957

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2003785594

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007082953

Country of ref document: US

Ref document number: 10539793

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10539793

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2003785594

Country of ref document: EP